Clinical Trials Logo

Uterine Tone Disorders clinical trials

View clinical trials related to Uterine Tone Disorders.

Filter by:
  • None
  • Page 1

NCT ID: NCT06284421 Recruiting - Clinical trials for Cesarean Section Complications

Durometer for Measuring Uterine Tone

Start date: February 8, 2024
Phase: N/A
Study type: Interventional

This study will evaluate the use of a durometer to measure uterine tone in parturients undergoing cesarean delivery.

NCT ID: NCT03303235 Withdrawn - Clinical trials for Postpartum Hemorrhage

Intravenous Versus Intramuscular Administration of Methylergonovine for Uterine Contraction in Cesarean Sections

Start date: July 2020
Phase: Early Phase 1
Study type: Interventional

Insufficient uterine tone resulting in atony can potentiate hemorrhage and adverse outcomes for the parturient. Oxytocin is the first pharmacologic agent used, followed by methylergonovine, carboprost, and misoprostol. The American Congress of Obstetricians and Gynecologists (ACOG) recommends the sequential use of oxytocin, followed by methylergonovine, carboprost, misoprostol, then surgical intervention for cases of refractory uterine atony. Many studies have examined the effect and dosage of intravenous uterotonics, including oxytocin. Although there are anecdotal reports of using intravenous bolus or rapid infusion of methylergonovine, no randomized trial has compared efficacy and side effects of these two routes of administration. Investigators hypothesize that intravenous methylergonovine reduces the time to adequate uterine tone (the tone at which the uterus is adequately contracted to prevent atony after delivery of neonate), decreases the total dose of methylergonovine to contract the uterus, and therefore produces fewer side effects of hypertension, nausea, and vomiting. Reducing the time to achieve adequate uterine tone is likely to decrease postpartum hemorrhage.